Skip to main content
PIQRAY header image

Efficacy and safety

Learn about PIQRAY study results and what they mean to both oncologists and their patients in this roundtable discussion between Dr Dejan Juric, Dr Jules Cohen, Dr Mohammad Jahanzeb, and Dr Chaitali Nangia.

PIQRAY clinical data

Hear from Dr Sramila Aithal

Watch Dr Sramila Aithal, Chief of Medical Oncology and Director for Breast Center of Excellence at Cancer Treatment Centers of America, explain why she picks hope by knowing there is a specific treatment for her patients with HR+/HER2- aBC with a PIK3CA mutation.

Efficacy & safety

Learn about PIQRAY study results and what they mean to both oncologists and their patients in this roundtable discussion between Dr Dejan Juric, Dr Jules Cohen, Dr Mohammad Jahanzeb, and Dr Chaitali Nangia.

Patient management

Preparing your patients for PIQRAY

Clinical oncology pharmacist Heather Moore shares how her team works with patients to set expectations and prepare for treatment with PIQRAY.

PIQRAY patient journey

Hear from Dr Stephen Malamud and Dr Aixa Soyano about a patient's disease history, metastatic diagnosis, and treatment with PIQRAY.

Hyperglycemia management

Dr Dejan Juric discusses the management of hyperglycemia with Dr Jules Cohen, Dr Mohammad Jahanzeb, and Dr Chaitali Nangia.

PIK3CA mutations and testing

Hear from Dr Gregory Vidal

Watch Dr Gregory Vidal, a medical oncologist at the West Cancer Center and Research Institute, discuss the importance of knowing a patient's mutation status when considering their treatment options.

Mutation matters

View an expert discussion about why PIK3CA mutations matter in HR+/HER2- aBC patients. Dr Dejan Juric discusses mutations with Dr Jules Cohen and Dr Chaitali Nangia.

PIQRAY mechanism of action

PIQRAY works synergistically with fulvestrant across both the PI3K and ER pathways, respectively. Learn more about the mechanism of action behind PIQRAY. Based on in vitro/in vivo studies. Preclinical activity does not necessarily correlate with clinical outcomes.

Important Safety Information

PIQRAY is contraindicated in patients with severe hypersensitivity to it or any of its components. 

Severe Hypersensitivity: Severe hypersensitivity reactions, including anaphylaxis and anaphylactic shock, can occur in patients treated with PIQRAY. Severe hypersensitivity reactions were manifested by symptoms including, but not limited to, dyspnea, flushing, rash, fever, or tachycardia...

Indication

PIQRAY® (alpelisib) tablets is indicated in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer as detected by an FDA-approved test following progression on or after an endocrine-based regimen...

Click or scroll to see IMPORTANT SAFETY INFORMATION AND INDICATION
Reference: 1. Piqray [prescribing information]. East Hanover, NJ; Novartis Pharmaceuticals Corp.